

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173745 A1

(51) International Patent Classification:

A61K 31/444 (2006.01) A61P 25/14 (2006.01)
A61K 31/426 (2006.01) A61P 25/08 (2006.01)
A61K 31/4162 (2006.01)

(21) International Application Number:

PCT/US2024/016080

(22) International Filing Date:

16 February 2024 (16.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/446,711 17 February 2023 (17.02.2023) US

(71) Applicant: **CORCEPT THERAPEUTICS INCORPORATED** [US/US]; 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(72) Inventors: **HUNT, Hazel**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **BELANOFF, Joseph**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **MEIJER, Onno C.**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **GENTENAAR, Max**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **VAN ROON-MOM, Willeke M.C.**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(54) Title: METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS




FIG. 1F

(57) **Abstract:** Methods and compositions for treating a patient suffering from Huntington's Disease or for treating symptoms of Huntington's Disease are disclosed. The methods include administration of an effective amount of a heteroaryl ketone fused azadecalin glucocorticoid receptor modulator (GRM) or an octahydro fused azadecalin GRM to the patient. In embodiments, the GRM is dazucorilant. In embodiments, the GRM is zavacorilant. In embodiments, the GRM is orally administered. In some embodiments, the GRM is administered daily; in other embodiments, the GRM is administered on a schedule such as, e.g., once every other day, once every three days, once per week, or other administration schedule. Symptoms of Huntington's Disease that may be treated by the present methods include, without limitation, motor symptoms (e.g., muscle weakness, postural irregularities, difficulty walking, difficulty swallowing), and neurological or psychological symptoms (e.g., epileptic seizures, amnesia; confusion; impaired speech; delirium; depression; anxiety).

[Continued on next page]

(74) **Agent:** GAO, Chuan et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))